RT Journal Article
SR Electronic
T1 Superior immunogenicity and effectiveness of the 3rd BNT162b2 vaccine dose
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.12.19.21268037
DO 10.1101/2021.12.19.21268037
A1 Lustig, Yaniv
A1 Gonen, Tal
A1 Melzer, Lilac
A1 Gilboa, Mayan
A1 Indenbaum, Victoria
A1 Cohen, Carmit
A1 Amit, Sharon
A1 Jaber, Hanaa
A1 Doolman, Ram
A1 Asraf, Keren
A1 Rubin, Carmit
A1 Fluss, Ronen
A1 Mendelson, Ella
A1 Freedman, Laurence
A1 Regev-Yochay, Gili
A1 Kreiss, Yitshak
YR 2021
UL http://medrxiv.org/content/early/2021/12/21/2021.12.19.21268037.abstract
AB In a prospective cohort study involving 12,413 Health Care Workers (HCW), we assessed immunogenicity, vaccine-effectiveness (VE) and safety of the third BNT162b2 vaccine dose. One month after third dose, anti-RBD-IgG were induced 1.7-folds compared to one month after the second. A significant increase in avidity from 61.1% (95%CI:56.1-66.7) to 96.3% (95%CI:94.2-98.5) resulted in a 6.1-folds neutralizing antibodies induction. Linear mixed model demonstrated that the third dose elicited a greater response among HCW≥60 or those with ≥two comorbidities who had a lower response following the second dose. VE of the third dose relative to two doses was 85.6% (95% CI, 79.2-90.1%). No serious adverse effects were reported. These results suggest that the third dose is superior to the second dose in both quantity and quality of IgG-antibodies and safely boosts protection from SARS-CoV-2 infection by generating high avidity antibodies to levels that are not significantly different between healthy and vulnerable populations.Competing Interest StatementThe authors have declared no competing interest.Funding StatementSelf funded by the Sheba Medical CenterAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Sheba Medical Center IRB committeeI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors